



HAL
open science

Three Candidate Probiotic Strains Impact Gut Microbiota and Induce Anergy in Mice with Cow's Milk Allergy Downloaded from

Nathalie Esber, Aurélie Mauras, Johanne Delannoy, Chantal Labellie, Camille Mayeur, Marie-Aurore Caillaud, Toma Kashima, Landry Souchaud, Ioannis Nicolis, Nathalie Kapel, et al.

► To cite this version:

Nathalie Esber, Aurélie Mauras, Johanne Delannoy, Chantal Labellie, Camille Mayeur, et al.. Three Candidate Probiotic Strains Impact Gut Microbiota and Induce Anergy in Mice with Cow's Milk Allergy Downloaded from. *Applied and Environmental Microbiology*, 2020, 86 (21), 10.1128/AEM.01203-20 . hal-03007714

HAL Id: hal-03007714

<https://hal.sorbonne-universite.fr/hal-03007714>

Submitted on 16 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.



L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



Three Candidate Probiotic Strains Impact Gut Microbiota and Induce Anergy in Mice with Cow's Milk Allergy

Nathalie Esber,^{a*} Aurélie Mauras,^a Johanne Delannoy,^a Chantal Labellie,^a Camille Mayeur,^c Marie-Aurore Caillaud,^{a*} Toma Kashima,^{a*} Landry Souchaud,^{a*}  Ioannis Nicolis,^b Nathalie Kapel,^{a,d}  Anne-Judith Waligora-Dupriet^a

^aUMR-S 1139, Université de Paris, INSERM, Paris, France

^bUR 7537—BioSTM, Université de Paris, Paris, France

^cMicalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, Jouy-en-Josas, France

^dDepartment of Coprology, APHP Sorbonne Université, Pitie-Salpetriere Hospital, Paris, France

ABSTRACT Cow's milk allergy is a worldwide public health issue, especially since there is no effective treatment, apart from milk and dairy product avoidance. The aim of this study was to assess the beneficial role of three probiotic strains previously selected for their prophylactic properties in a mouse model of β -lactoglobulin allergy. Administration of *Lactobacillus rhamnosus* LA305, *L. salivarius* LA307, or *Bifidobacterium longum* subsp. *infantis* LA308 for 3 weeks post-sensitization and challenge modified the composition of the gut microbiota, with an increase in the *Prevotella* NK3B31 group and a decrease in *Marvinbryantia*, belonging to the *Lachnospiraceae* family. Although no impact on markers of sensitization was detected, modifications of *foxp3*, *tgfb*, and *il10* ileal gene expression, as well as plasma metabolomic alterations in the tryptophan pathway, were observed. Moreover, *ex vivo* studies showed that all probiotic strains induced significant decreases in cytokine production by β -lactoglobulin-stimulated splenocytes. Taken together, these results suggest that the three probiotic strains tested lead to alterations in immune responses, i.e., induction of a tolerogenic anergy and anti-inflammatory responses. This anergy could be linked to cecal microbiota modifications, although no impact on fecal short-chain fatty acid (SCFA) concentrations was detected. Anergy could also be linked to a direct impact of probiotic strains on dendritic cells, since costimulatory molecule expression was decreased following cocubation of these strains with bone marrow-derived dendritic cells (BMDCs). To conclude, all three candidate probiotic strains induced strain-specific gut microbiota and metabolic changes, which could potentially be beneficial for general health, as well as anergy, which could contribute to oral tolerance acquisition.

IMPORTANCE We showed previously that three probiotic strains, i.e., *Lactobacillus rhamnosus* LA305, *L. salivarius* LA307, and *Bifidobacterium longum* subsp. *infantis* LA308, exerted different preventive effects in a mouse model of cow's milk allergy. In this study, we evaluated their potential benefits in a curative mouse model of cow's milk allergy. When administered for 3 weeks after the sensitization process and a first allergic reaction, none of the strains modified the levels of sensitization and allergic markers. However, all three strains affected gut bacterium communities and modified immune and inflammatory responses, leading to a tolerogenic profile. Interestingly, all three strains exerted a direct effect on dendritic cells, which are known to play a major role in food sensitization through their potentially tolerogenic properties and anergic responses. Taken together, these data indicate a potentially beneficial role of the probiotic strains tested in this model of cow's milk allergy with regard to tolerance acquisition.

KEYWORDS probiotics, food allergy, cow's milk allergy, murine model, gut microbiota, dendritic cells, anergy

Citation Esber N, Mauras A, Delannoy J, Labellie C, Mayeur C, Caillaud M-A, Kashima T, Souchaud L, Nicolis I, Kapel N, Waligora-Dupriet A-J. 2020. Three candidate probiotic strains impact gut microbiota and induce anergy in mice with cow's milk allergy. *Appl Environ Microbiol* 86:e01203-20. <https://doi.org/10.1128/AEM.01203-20>.

Editor Edward G. Dudley, The Pennsylvania State University

Copyright © 2020 Esber et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Anne-Judith Waligora-Dupriet, anne-judith.waligora@u-paris.fr.

* Present address: Nathalie Esber, AgileBio SARL, Créteil, France; Marie-Aurore Caillaud, Toulouse Biotechnology Institute, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France; Toma Kashima, Laboratory of Enzymology, Department of Biotechnology, The University of Tokyo, Tokyo, Japan; Landry Souchaud, Transition careers, Master's degree in teaching, education and training (MEEF), Université de Poitiers, Poitiers, France.

Received 2 June 2020
Accepted 23 July 2020

Accepted manuscript posted online 21 August 2020

Published 15 October 2020

Cow's milk allergy (CMA) is one of the most common allergic disorders in infants and young children, particularly in the industrialized world, where its prevalence reaches 2 to 7.5% in infants, without any marked variation over the past decade (1). CMA is manifested by a variety of symptoms and signs, including life-threatening anaphylaxis, and is commonly associated with stunted growth (2). Although it usually regresses by the age of 5 or 6 years, CMA is still a source of stress for families due to the need to follow a milk-free diet and can lead to subsequent nutritional deficiency if not treated appropriately. The World Allergy Organization Special Committee on Food Allergy has therefore identified CMA as an area in need of a rationale-based approach to a problem that is considered serious, with a worldwide public health impact, especially since there are no effective therapeutic measures apart from food avoidance and lengthy immunotherapy (3, 4).

Emerging evidence indicates that suboptimal establishment of the gut microbiota in early infancy represents a critical factor underlying the development of food allergy (FA) (5). Several birth cohort studies have shown an altered gut microbiota in infants with CMA versus healthy infants (6–8). Moreover, we and others have shown the protective role of a healthy microbiota and the deleterious role of a CMA-associated microbiota in humanized β -lactoglobulin (BLG)-sensitized mouse models (9, 10). Intestinal commensal bacteria and their sequential establishment are known to play a crucial role in the maturation of the intestinal immune system, modulation of the T-helper (Th) balance, acquisition of oral tolerance, and maintenance of gut wall epithelial integrity. These relationships between the intestinal microbiota, immune responses, and allergy have contributed to the concept of modulating the intestinal microbiota in order to prevent or manage allergic diseases, and they support the use of probiotics as anti-allergic therapy. However, in the context of FA, and CMA in particular, most studies have evaluated the preventive impact of various probiotic strains, while only a few have investigated their curative properties, with conflicting results (11). We previously identified three probiotic strains (*Lactobacillus rhamnosus* LA305, *L. salivarius* strain LA307, and *Bifidobacterium longum* subsp. *infantis* LA308) with prophylactic properties in a murine model of food allergy (specifically allergy to BLG), in particular decreasing specific IgE responses and mast cell degranulation (12). Our objective in this study was to evaluate the impact of these three probiotic strains in a curative murine model of BLG allergy.

RESULTS

None of the three probiotic strains tested regulated markers of sensitization or mast cell degranulation. The sequence of whey protein (WP) sensitization, challenge, and probiotic supplementation in our murine model of CMA is illustrated in Fig. 1A. Levels of BLG-specific IgE, expressing sensitization to WP, increased significantly during the five sensitization steps over those for the nonsensitized (NS) control group receiving cholera toxin (CT) alone ($P < 0.01$), reaching a median value on day 42 (D42) that corresponded to completion of the sensitization procedure (median optical density at 450 nm [OD₄₅₀], 0.85 [range, 0.21 to 1.47]), similar to that observed at D63 after the second BLG challenge (median OD₄₅₀, 1.15 [range, 0.38 to 1.66]). At D63, the end of the 20-day supplementation period, NS mice that received only CT showed low levels of mouse mast cell protease-1 (mMCP-1) and BLG-specific IgE, IgG1, and IgG2a in plasma, irrespective of whether they had been treated with probiotics. All WP-sensitized groups, whether treated with probiotics or not, showed significantly higher levels of mMCP1 and BLG-specific IgE, and higher IgG1/IgG2a responses, than those of the NS groups ($P < 0.01$). With regard to WP-sensitized mice, no statistically significant differences in levels of mMCP-1 and BLG-specific IgE, or in the IgG1/IgG2a ratio, were observed between any of the three probiotic-treated groups and the phosphate-buffered saline (PBS)-treated control group (Fig. 1B).

A 3-week supplementation with each of the three probiotic strains impacted gut microbiota in allergic mice without modifying short-chain fatty acid (SCFA) production. Microbiota analyses were performed on cecal contents (CC) at D63 using





FIG 1 Impact of probiotic treatment on mast cell degranulation and BLG-specific antibody responses after an oral challenge with β -lactoglobulin (BLG). (A) Scheme of the experiment. D, day. (B) After the second BLG challenge, plasma mMCP-1 and anti-BLG-specific IgE levels, and the anti-BLG-specific IgG1/IgG2a ratio, were determined by ELISA. Each point represents a mouse, and the central horizontal line represents the median result for each group. Data were compared to those for WP-sensitized mice treated with PBS by using the Mann-Whitney U test, *, $P < 0.05$; **, $P < 0.01$.

16S rRNA gene sequencing. A total of 624 operational taxonomic units (OTUs) were identified. Among these, we selected for further analysis 454 OTUs, comprising the 99% most abundant OTUs, belonging to 7 phyla, 22 families, and 64 genera. Analyses were performed at the genus level. The three probiotic strains modified the microbiota in different ways (Fig. 2A). Only treatment with *L. rhamnosus* LA305 after the first BLG challenge significantly increased microbiota richness ($P < 0.05$), increasing the number of OTUs over that for the PBS-treated group (Fig. 2B). However, these modifications did not affect α -diversity expressed as the Shannon index (Fig. 2B). Supplementation with LA305 led to a modification in dominant, phylogenetically unrelated genera, as well as in subdominant genera, as evidenced by the fact that β -diversity differed significantly between the PBS- and LA305-treated groups whether calculated according to Bray-




FIG 2 Microbiota analysis in sensitized mice. (A) Relative abundances of bacterial families in cecal samples (n, 6 to 7/group). (B) α -Diversity between the groups. The y axes show the numbers of species observed (left) and the Shannon diversity index (right). The box plots show (Continued on next page)

Downloaded from <http://aem.asm.org/> on November 16, 2020 by guest

Curtis (Fig. 2C), UniFrac (Fig. 2F), or Jaccard (data not shown) distances. Treatment with *L. salivarius* LA307 did not affect α -diversity, but the composition of phylogenetically unrelated subdominant genera was modified, as evidenced by the fact that β -diversity differed significantly between the PBS- and LA307-treated groups when calculated on the basis of UniFrac (Fig. 2G) and Jaccard (data not shown) distances but not when calculated according to Bray-Curtis distance (Fig. 2D). In contrast, *B. longum* subsp. *infantis* LA308 altered only dominant, phylogenetically related genera, as evidenced by the fact that β -diversity differed significantly from the PBS group only when calculated according to Bray-Curtis distance (Fig. 2E) and not when calculated according to UniFrac distance (Fig. 2H).

The numbers of genera that significantly differentiated the microbiota of probiotic-treated mice from that of PBS-treated mice were 17, 4, and 8 for LA305, LA307, and LA308, respectively (Fig. 2I; see also Fig. S1 and Table S1 in the supplemental material). Two genera were similarly affected by all three probiotic strains: the *Prevotellaceae* NK3B31 group was increased, and the *Marvinbryantia* genus, belonging to the *Lachnospiraceae* family, was decreased. The microbiotas of LA305- and LA307-treated mice were enriched in *Odoribacter* spp., whereas levels of this genus were lower in the microbiota of LA308-treated mice than in the PBS group. Other modifications unique to a particular probiotic strain were observed, confirming the strain-specific impact of probiotics on the microbiota. For instance, apart from that of *Marvinbryantia*, LA305 modified the abundances of several genera belonging to the *Firmicutes*, increasing those of some *Peptococcaceae* and *Ruminococcaceae*, and decreasing that of *Clostridium sensu stricto*. It also decreased the abundances of *Deferribacteres* (*Mucispirillum* spp.), *Epsilonbacteraeota* (*Helicobacter* spp.), and *Proteobacteria* (*Ralstonia* spp. and *Rhodospirillales*). In contrast, LA308 increased the abundance of the *Lachnospiraceae* NK4A136 group, altered the composition of *Proteobacteria* (decreasing *Bilophila* spp. and increasing *Desulfovibrio* spp.), and decreased the abundance of *Anaeroplasma*. It should be noted that our analyses did not show any modification in species of *Lactobacillus*, a major genus within the mouse intestinal microbiota, or in *Bifidobacterium* spp., which are at low levels, regardless of the probiotic strain administered.

Despite these modifications in the gut microbiota, fermentative activities and short-chain fatty acid production after probiotic treatment were not modified from that with PBS treatment, irrespective of the strain tested (Fig. S2).

All three probiotic strains decreased *ex vivo* secretion of T-helper cell cytokines in response to allergen challenge. The T-helper response to antigen challenge was evaluated by measuring the quantities of cytokines secreted into culture supernatants by splenocytes isolated from WP-sensitized mice supplemented with the three probiotics tested or PBS (controls) and cultured *ex vivo* in the presence or absence of BLG. Splenocytes cultured in the absence of BLG secreted very small amounts of cytokines (data not shown) in contrast to splenocytes from PBS-treated mice exposed to BLG challenge. Cytokine secretions by splenocytes isolated from mice that had received probiotic supplementation were lower than those by splenocytes isolated from control mice that had received only PBS, suggesting a possible anergic effect of the probiotics. In particular, splenocytes isolated from mice treated with each of the three probiotics secreted significantly lower quantities of granulocyte-macrophage colony-stimulating factor (GM-CSF), gamma interferon (IFN- γ), interleukin 2 (IL-2), and IL-4 than splenocytes from PBS controls (Fig. 3). Decreases in the secretion of other cytokines were strain specific. Significant decreases in the secretion of IL12p70 ($P < 0.01$) and IL-10

FIG 2 Legend (Continued)

the median (central horizontal line), the 25th percentile (lower box border), and the 75th percentile (upper box border). The lower and upper horizontal lines show the 10th and 90th percentiles, respectively. *, $P < 0.05$. (C to H) β -Diversity observed with Bray-Curtis distance (C to E) and UniFrac distance (F to H). Scatterplots were generated using constrained analysis of principal coordinates (CAP). Mice that received PBS only are represented in blue. Probiotic groups are represented in red for LA305 (C and F), LA307 (D and G), and LA308 (E and H). β -Diversity was compared to that of WP-sensitized mice treated with PBS by use of PERMANOVA. (I) CAP-ordinated heat maps of cecal bacteria in the four groups of mice at the genus level. The genera indicated are derived from SIMPER and LefSe analyses and discriminated one or several of the groups receiving probiotics from the group receiving PBS.




FIG 3 Impact of probiotic treatment on *ex vivo* cytokine secretion by BLG-stimulated splenocytes. Splenocytes isolated at D63 from WP-sensitized mice were rechallenge *ex vivo* for 2 days in the presence of BLG (2.5 mg/ml). Each point represents a mouse, and the central horizontal line represents the median of each group. Cytokine concentrations in culture supernatants of splenocytes from probiotic-treated WP-sensitized mice versus PBS controls were compared using the Mann-Whitney U test (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$).

($P < 0.05$) were observed in the culture supernatants of splenocytes isolated from LA305-treated mice, whereas no effect on IL-5 levels was observed. In contrast, splenocytes isolated from LA307-treated mice secreted significantly less IL-5 ($P < 0.001$) and IL17A ($P < 0.01$), whereas no effect on IL-10 was seen. Splenocytes isolated from LA308-treated mice showed the same profile of decreases in cytokine secretion as those from LA307-treated mice except for a lack of effect on IL17A secretion (Fig. 3).

The three probiotic strains tested had different effects on T-helper cell transcription pathways in the ileum. The effect of probiotic treatment on T-helper cell




FIG 4 Impact of probiotic treatment on the ileal local immune response profile. The expression of ileal gene mRNA (*foxp3*, *tgfb*, and *il10*) in sensitized mice (n , 12 for each probiotic group) was quantified by quantitative real-time PCR and normalized to expression for the sensitized PBS control group (n = 10). Data are expressed as means \pm SEM. Data were compared to those for PBS-treated WP-sensitized mice using the Mann-Whitney U test (*, P < 0.05; **, P < 0.01).

pathways in the terminal ileum was evaluated through analyses of gene expression of cytokines and transcription factors related to the T-helper cell subsets Th1, Th2, and Th17, as well as regulatory T cells (Treg cells). None of the probiotics tested had a significant impact on T-helper cell gene expression in WP-sensitized mice (data not shown). However, all three probiotic strains affected the expression of genes linked to Treg cells and anergy (Fig. 4). Treatment with LA305 or LA307 significantly increased *foxp3* (P , <0.01 and <0.05, respectively), *tgfb* (P , <0.05 and <0.01, respectively), and *il10* (P , <0.01 and <0.01, respectively) mRNA expression, while LA308 induced an increase only in *tgfb* gene expression (P < 0.05).

All three probiotic strains modified plasma kynurenic metabolism. The effect of probiotic treatment on metabolic pathways was evaluated through metabolomic analyses of plasma samples. Seven hundred named biochemicals were detected. LA305, LA307, and LA308 significantly modified the abundances of 47, 30, and 19 of these compounds, respectively, from those with PBS treatment. The quantities of certain microbial metabolites usually found in plasma under normal conditions were modified by probiotic treatment; e.g., *p*-cresol sulfate was decreased 3.8-fold by LA305, and phenol sulfate showed a trend to decrease (1.7-fold) with LA308. Changes in the abundances of certain modified lysines and RNA-related biochemicals were observed with LA308, and the quantities of certain compounds implicated in the citric acid cycle pathway were modified by LA305 and LA308 supplementation. However, the physiological consequences of these changes, such as histone deacetylation or demethylation, were difficult to determine at this level. Analysis of the tryptophan pathway, known to be associated with tolerance acquisition, showed that all three probiotic strains induced significant decreases in kynurenine and *N*-acetylkynurenine levels from those with PBS treatment, while none of the probiotics affected the levels of tryptophan, serotonin, or indole-acetate in plasma (Fig. 5).

All three probiotic strains impacted BDMC maturity. Bone marrow-derived dendritic cells (BMDCs) isolated from BALB/cByJ mice were used to evaluate the immunomodulatory properties of the three probiotic strains, since these cells are a relevant model of DCs, as shown previously through their *in vitro* and *in vivo* interactions with T cells (13, 14). Stimulated BMDCs express costimulatory molecules on their surfaces, allowing them to present the processed antigens associated with major histocompatibility complex class II (MHC-II) molecules. In all our experiments, we targeted CD11c⁺ cells, which represented 80% \pm 2.8% of total cells whatever the incubation conditions. Under basal conditions, approximately 80% of CD11c⁺ cells expressed CD86 and MHC-II, and 70% expressed the costimulatory molecule CD80 (Fig. 6). Coincubation with PAM2CSK4, which is a Toll-like receptor 2 (TLR-2) agonist, or with CpG oligodeoxynucleotide (ODN), which is a TLR-9 agonist, did not alter this expression profile. Following an 18-h coincubation period, LA305 induced significant decreases in MHC-II (2-fold), CD80 (2.2-fold), and CD86 (24-fold) expression on BMDCs. LA307 induced the




FIG 5 Impact of probiotic treatment on the tryptophan pathway. The metabolomes in plasma samples from WP-sensitized PBS-treated ($n = 5$) and probiotic-treated ($n = 5$ for each probiotic group) mice were analyzed by Metabolon using UPLC-MS/MS. To allow comparison of all biochemicals on a similar scale, the scaled imputed data method was used (i.e., the median value was set to 1, and all other values were scaled accordingly). The box plots show the median (central horizontal line), the 25th percentile (lower box border), and the 75th percentile (upper box border). The lower and upper horizontal lines show the 10th and 90th percentiles, respectively. Data were compared to those for PBS-treated WP-sensitized mice using the Mann-Whitney U test (*, $P < 0.05$; **, $P < 0.01$).

same expression profile with 1.9-fold, 2.7-fold, and 59-fold decreases in MHC-II, CD80, and CD86 expression, respectively. In contrast, LA308 did not significantly modify the expression of costimulatory molecules on BMDCs. However, all three strains significantly increased IL-10 secretion by BMDCs ($P < 0.01$ for LA305 and LA307 and < 0.05 for LA308). Such increased secretion was not observed on analysis of the culture supernatants of unstimulated BMDCs or BMDCs coincubated with TLR-2 and TLR-9 agonists.

DISCUSSION

In this study, we showed that the postchallenge administration of three candidate probiotic strains, two belonging to the *Lactobacillus* genus and one to the *Bifidobacterium* genus, for 3 weeks in a murine model of CMA induced gut microbiota and immune response alterations, i.e., tolerogenic energy and low inflammatory status, although no impact on serum markers of sensitization was observed. The three probiotic strains, *L. rhamnosus* LA305, *L. salivarius* LA307, and *B. longum* subsp. *infantis* LA308, had been selected in a previous study out of a panel of 31 strains for their




FIG 6 Impact of the three probiotic strains on BMDC maturation. Probiotic strains were coincubated with BMDCs (results from three experiments performed, each with three independent bacterial cultures). BMDCs without stimulation were used as an experimental control, and PAM2CSK4 (a TLR-2 ligand) and CpG-ODN (a TLR-9 ligand) were used as controls. The maturation of BMDCs was evaluated by FACS analysis: MHC-II, CD80, CD86. CD11c was used as a BMDC surface marker. The supernatant was collected, and interleukin-10 was measured by ELISA. Results are expressed as means \pm SEM. Data were compared to those for nonstimulated BMDCs by using the Mann-Whitney U test (*, $P < 0.05$; **, $P < 0.01$).

prophylactic properties (12). In the present study, we evaluated their therapeutic potential in a murine model of CMA. Sensitization of mice with WP was previously shown to induce high levels of specific IgE and IgG1 antibodies, and a substantial release of mMCP-1 was observed following allergen challenge (12). In the study reported here, none of the three probiotic strains modified this natural evolution when administered daily after the first challenge. This result could have been due to the short duration of administration compared to IgG1- and IgE-producing cell half-lives (15, 16). However, a similar study using ovalbumin instead of WP for sensitization and administration of a synbiotic mixture of nondigestible oligosaccharides and *Bifidobacterium breve* M-16V reported beneficial results on allergy markers (17). In the model described here, the initial BLG challenge performed at D42, i.e., before the administration of probiotics, might have modified the allergic response at D63. Despite the absence of beneficial effects on the serologic markers of sensitization and allergy, the 20-day supplementation performed after the first challenge led to a marked decrease in the secretion of all cytokines when splenocytes were subjected to allergen stimulation *ex vivo*. Such a reduction of allergen-specific Th2 cytokine production has been already described after oral immunotherapy and is attributed mainly to T-cell anergy, i.e., T-cell unresponsiveness to the antigen (18). The three probiotic strains were thus able to induce anergy, a mechanism known to contribute to oral tolerance (19). Anergy is a mechanism supported by recent human studies for oral tolerance. Its induction could be related to the stimulation of Treg cells. Indeed, supplementation with either LA305 or LA307 induced an increase in ileal expression of *foxp3*, *tgfb*, and *il10*. However, the mechanism by which the three strains could induce Treg-cell development is not clear. Treg-cell induction could be related to the production of immunoregulatory metabo-

lites, particularly acetate, propionate, and butyrate, by the intestinal microbiota (20), since SCFAs have previously been proposed to suppress food allergy by eliciting protective mucosal Treg-cell responses and enhancing intestinal barrier integrity (21). However, we did not detect any significant variation in SCFA concentrations after probiotic treatment whatever the strain used, although all three probiotic strains impacted gut microbiota, including an enrichment of *Odoribacter* spp. following LA305 and LA307 treatment, *Odoribacter splanchnicus* being a known producer of acetate, propionate, and butyrate (22). Similar results have been reported by Abdel-Gadir et al., who found no correlation between the production of SCFAs by bacterial consortia or SCFA oral administration and their efficacy in treating food allergy in mice (23). Another potential link between the composition of the gut microbiota and Treg induction relies on the ability of the microbiota to regulate the tryptophan pathway, which is associated with a protolerogenic Treg-cell response through the production of a variety of bioactive compounds, such as kynurenine (24). We did not detect any increase in tryptophan metabolites such as kynurenine or acetyl-kynurenine, but a decrease. Georin-Lavialle et al. reported a significant decrease in the serum tryptophan level associated with an increase in the kynurenine level and indoleamine 2,3-dioxygenase (IDO) activity in patients with mastocytosis associated with digestive symptoms compared to healthy controls and patients without such symptoms (25). In our model, the sensitization process leads transiently to digestive symptoms (9); the decrease of the kynurenine pathway observed following probiotic administration could therefore be a marker of improved digestive health related to less inflammation in the probiotic-treated groups.

Since we did not identify any argument suggesting the implication of classical pathways with active suppressive Treg-cell induction by the microbiota, we focused our research on another mechanism of T-cell anergy. Indeed, reduction of allergen-specific Th2 cytokine production observed after oral immunotherapy for food allergy has been attributed mainly to T-cell anergy, while the generation of Treg cells in this process is not clear (18, 26). Interestingly, the *Prevotella* NK3B31 group was increased in the three probiotic-treated groups of mice. A decrease in *Prevotella* spp. has been reported in allergic infants and children (27), and an increase in this bacterial group was associated with the protective effect of prebiotic treatment in a CMA mouse model (28). Moreover, *Prevotella intermedia* has been demonstrated to have immunosuppressive effects on *in vitro* human lymphocyte activation, inhibiting the release of cytokines and expression of the interleukin 2 receptor and CD69 on T cells (29), a mechanism of action in accordance with our observations. Similarly, a significant increase in *Lachnospiraceae* has been reported in children with CMA (8), and *Marvinbryantia*, a genus belonging to the *Lachnospiraceae* family, was decreased by all three probiotic strains tested in our study. Although no specific mechanism could be determined based on these data, our principal aim was to assess the direct role of these strains.

Anergy can be induced by dendritic cells. The impact of these key players in the acquisition of tolerance depends on their cytokine production pattern and expression of costimulatory molecules (30). Following *in vitro* coinubation with BMDCs, the two lactobacillus strains decreased MHC-II, CD80, and CD86 costimulatory molecule expression at the surfaces of dendritic cells. These cells are in a semimature state and can exert tolerogenic effects via the induction of anergy (31). Indeed, anergy is induced following recognition of the antigen by T cells in the absence of costimulatory signals, that is, the binding of CD28 on their surfaces to its ligand, CD80/CD86 on dendritic cells (32). Moreover, in our study, coinubation with LA305 and LA307 induced a pronounced increase in production of the regulatory cytokine IL-10 by dendritic cells. While it had no effect on costimulatory molecules on BMDCs, LA308 also induced a similar increase in IL-10 production.

In our previous study, using a prophylactic mouse model, the three probiotic strains had distinct immune profiles. LA307 was rather immunosuppressive, with no impact on IFN- γ and IL-10 production, and could stimulate Treg cells. LA308 increased the

production of Th1 cytokines, which inhibit the proliferation of Th2 cells, whereas LA305 had pro-Th1 and regulatory effects (12).

In this study, we show that the three probiotic strains administered postsensitization in our curative model of CMA led to modification of the gut microbiota (LA305 having a major impact compared to the other two strains) as well as to the development of tolerogenic anergy. Impact on gut microbiota is a proof of concept, since the mouse gut microbiota could not be compared to the human gut microbiota. However, we speculate that several modifications of the microbiota induced by LA305 could reinforce this effect. *Ralstonia* spp., known for their proinflammatory effects, were depleted, as previously observed by Fu et al. following *Lactobacillus* treatment in another CMA mouse model (33). Similarly, *Clostridium sensu stricto*, a genus that has been associated with the microbiota of allergic children harboring an IgE-dependent food allergy or atopic dermatitis (34, 35), was also decreased. In contrast, LA308 belongs to the *Bifidobacterium* group, a bacterial genus that is not as well adapted as lactobactobacilli to the mouse gut ecosystem. This could explain why this strain had an impact on the microbiota and metabolome different from those of the two *Lactobacillus* strains.

In conclusion, oral administration of the three candidate probiotic strains to mice with induced allergy to BLG led to microbial and metabolic changes that could potentially be beneficial for general health, as well as to anergy, which could play a role in oral tolerance acquisition (Fig. 7). Immunotherapy is recommended for children with persistent CMA over the age of 4 to 5 years but has been associated with significant risks (36). Therefore, these probiotic strains could be useful as adjuvants in desensitization processes, as reported for a strain of *L. rhamnosus* combined with oral immunotherapy of peanut allergy (37). Clinical studies would have to be performed to confirm these experimental results and to determine which is the most effective of the three probiotic strains tested.

MATERIALS AND METHODS

Animals and housing conditions. Three-week-old conventional female BALB/cByJ mice were purchased from Charles River Laboratories (CRL; L'Arbresle, France). Mice were housed under conventional conditions in adapted and enriched cages maintained under a 12-h light-dark cycle, in temperature- and humidity-controlled chambers. They had free access to water and mouse pellets lacking cow's milk proteins (A03; SAFE, Augy, France). All animal experiments began after 1 week of adaptation. All procedures were carried out in accordance with European guidelines for the care and use of laboratory animals. The protocol was approved by the Regional Council of Ethics for animal experimentation (Ile de France-Paris Descartes, CEEA34.AJWD.062.12). Experiments were performed in the animal care facilities of the CRP2-UMS 3612 CNRS-US25 INSERM-IRD unit in the Faculty of Pharmacy of Paris Descartes University, Paris, France.

Mouse model of β -lactoglobulin food allergy: sensitization and probiotic administration. Our model was adapted from the work of Li et al. (38). After an adaptation period, female BALB/cByJ mice were either sensitized once a week for 5 weeks by intragastric administration of WP (15 mg/mouse; Lacprodan 80; Arla, Lyon, France) and CT (10 μ g/mouse; List Biological, Campbell, CA) suspended in 100 μ l of PBS (sensitized group) or treated with 10 μ g CT alone in PBS (nonsensitized group) (Fig. 1). On D42, an initial challenge was performed by oral administration of 60 mg of BLG (Sigma-Aldrich, France). On the following day, to avoid a cage effect associated with the sensitization process, the mice were randomly assigned to new cages and either to one of the three probiotic groups or to the PBS control group. Each of these groups included two subgroups: sensitized mice (n , 12 in each probiotic group and 10 in the PBS group) and nonsensitized mice (n , 6 in each probiotic group and 5 in the PBS group). In the probiotic groups, mice received daily, for 20 days (from D43 to D62), a single lyophilized bacterial strain (10^9 CFU), either *Lactobacillus rhamnosus* LA305, *L. salivarius* LA307, or *Bifidobacterium longum* subsp. *infantis* LA308 (Genibio, Lorp-Sentaraille, France), suspended in 200 μ l of PBS. The dose we chose to use is the one we used to demonstrate the preventive effect of these three strains on BLG allergy (12). Gavage was performed by two researchers who rotated between cages every 2 days. Mice in the control group received 100 μ l of sterile PBS. On D63, all mice received a second oral challenge comprising administration of 60 mg of BLG (Fig. 1A).

Measurements of mast cell protease-1 and BLG-specific IgE, IgG1, and IgG2 antibodies in plasma. Blood from each mouse was collected in K₃-EDTA tubes 45 min after the second BLG challenge. The blood samples were immediately centrifuged (at 3,000 rpm for 10 min at 4°C), and plasma samples were stored at -80°C until use. Concentrations of mouse mast cell protease-1 (mMCP-1) in plasma were measured by an enzyme-linked immunosorbent assay (ELISA) (Mouse MCPT-1 [mMCP-1] ELISA kit; Invitrogen, Thermo Scientific, Illkirch, France) according to the manufacturer's instructions. BLG-specific IgE, IgG1, and IgG2a levels were measured as described previously (39). Briefly, BLG-specific IgE levels




FIG 7 Overview of the proof of concept. Administration of one of the probiotic strains modulates the composition and diversity of the intestinal microbiota and downregulates the expression of costimulatory molecules on the surfaces of dendritic cells. These cells are in a state of semimaturity and do not activate helper T cells, resulting in anergy, with a decrease in the production and secretion of the cytokines involved in the allergic reaction. In particular, the decrease in proinflammatory cytokines, which are known to activate IDO, leads to a decrease in kynurenine, a marker of inflammation, in the general circulation. The three probiotic strains could then play a role in the acquisition of oral tolerance.

were measured using a rat anti-mouse IgE antibody (Pharmingen, BD Biosciences, Le Pont-de-Claix, France) as the capture antibody and biotinylated BLG (Pierce, Rockford, IL) and streptavidin-horseradish peroxidase (HRP) (CliniSciences, Nanterre, France) as the detecting system. BLG-specific IgG1 and IgG2a were measured using BLG as the capture antigen and goat anti-mouse IgG1-HRP and IgG2a-HRP (CliniSciences, Nanterre, France) as the detecting antibodies. All analyses were performed in duplicate, and the results were expressed in terms of OD read at 450 nm. The IgG1/IgG2a ratio was calculated as a reflection of Th2/Th1 reactivity.

Measurement of cytokine production by BLG-stimulated splenocytes. Spleens were collected on the day of mouse sacrifice and were placed in sterile RPMI 1640 medium. Then splenocytes were isolated and cultured *ex vivo* as described previously (40). Briefly, spleens were gently crushed and filtered through a 70- μ m nylon filter (Falcon; Dutcher, Brumath, France). After elimination of red blood cells, splenocytes were resuspended in RPMI 1640 complete tissue culture medium (Gibco, Thermo Scientific, Illkirch, France) containing 1% penicillin-streptomycin, 2 mM L-glutamine, and 10% fetal calf serum. Splenocytes were cultured in 24-well plates at a density of 2×10^6 per well, with or without 2.5 mg/ml BLG at 37°C under an atmosphere of 5% CO₂ and 95% air. Culture supernatants were collected after 48 h and stored at -80°C until analysis.

Levels of IL-17A, IL-2, GM-CSF, IL-4, IFN- γ , IL-10, IL-5, and IL-12p70 in splenocyte culture supernatants were quantified using Bio-Plex immunoassay kits (Bio-Plex Pro cytokine panel and Luminex Bio-Plex 200 system; Bio-Rad, Life Science Group, Hercules, CA) according to the manufacturer's instructions.

Quantification of ileal gene expression by quantitative real-time PCR. On the day of mouse sacrifice, the ileum of each mouse was removed and stored in RNAlater at -80°C until RNA extraction. Total RNA was isolated from a 1-cm terminal ileum segment devoid of Peyer's patches by

using an RNeasy Plus universal minikit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. RNA was then treated with DNase I (Invitrogen, Thermo Scientific, Illkirch, France), and first-strand cDNA was synthesized from 500 ng of total RNA with SuperScript II and oligo(dT)₁₂₋₁₈ primers (Invitrogen, Thermo Scientific, Illkirch, France) as described previously (12). Quantitative real-time PCR was performed on an ABI Prism 7900HT sequence detection system (Applied Biosystems). TaqMan gene expression assays with TaqMan universal master mix II (Applied Biosystems, Thermo Scientific, Illkirch, France) were used to quantify the expression of *gata3*, *tbet*, *foxp3*, *roryt*, *ifn γ* , *tnf α* , *il4*, *il10*, and *tgfb*. Assays were performed in duplicate, and gene expression levels were calculated using the $2^{-\Delta\Delta CT}$ method (41), where C_T is the threshold cycle with the TATA box (TaqMan) assay as the reference gene. Fold increases in expression were normalized to expression levels in the sensitized PBS group.

Evaluation of the fermentative activity of the microbiota. The concentrations of short-chain fatty acids (SCFAs), i.e., acetate, propionate, butyrate, valerate, caproate, isobutyrate, isovalerate, and isocaproate, were measured in the cecal contents (CC) collected on the day of mouse sacrifice, which were immediately stored at -80°C . Analyses were performed according to the method of Lan et al. (42). After thawing at room temperature, samples were water-extracted, and proteins were precipitated with phosphotungstic acid. The samples were analyzed by gas chromatography using a system (Autosystem; Perkin-Elmer, St. Quentin en Yvelines, France) equipped with a split/splitless injector, a flame ionization detector, and a capillary column (length, 15 m; inside diameter, 0.53 mm; film thickness, 0.5 μm) impregnated with SP100 (Nukol; Supelco, Saint-Quentin-Fallavier, France). The temperatures of the injector, column, and detector were 200°C , 100°C , and 240°C , respectively. The internal standard was 2-ethylbutyrate. All samples were analyzed in duplicate. Data were collected, and peaks were integrated, using Turbochrom software (Perkin-Elmer, Courtaboeuf, France). Results were expressed in micromoles per gram of CC.

Metabolomic analyses. Metabolomic analyses were performed by Metabolon (Morrisville, NC, USA) on plasma from sensitized mice (5 to 6 samples per group) according to the procedure described previously (43). Briefly, following methanol extraction, the sample was divided into four fractions: two for analysis by two separate reverse-phase ultraperformance liquid chromatography–tandem mass spectrometry (RP-UPLC–MS/MS) methods with positive-ion-mode electrospray ionization (ESI), one for analysis by RP-UPLC–MS/MS with negative-ion-mode ESI, and one for analysis by hydrophilic interaction liquid chromatography (HILIC)/UPLC–MS/MS with negative-ion-mode ESI. Raw data were extracted, peak-identified, and quality control (QC)-processed using Metabolon's hardware and software. Compounds were identified by comparison to library entries or to chromatographic and spectral data of purified standards or recurrent unknown entities (>3,300 compounds), using several criteria, such as the retention index and mass-to-charge ratio (m/z). With regard to MS/MS spectral data, MS/MS forward and reverse scores were compared between the experimental data and authentic standards. A variety of curation procedures were carried out to ensure the availability of a high-quality data set for statistical analysis and data interpretation. Since each biochemical has its own scale of values, the median concentration of each compound was calculated, and the individual concentrations of the compound determined in the different samples were then divided by this median concentration. In this way, the median value of each compound was set at 1, allowing comparison of the relative concentrations of all the biochemicals on a common scale. Statistical analyses were performed after log transformation and imputation of missing values, if any, using the minimum observed value for each compound.

Microbiota analyses. Total bacterial DNA was extracted from the fecal contents of sensitized mice (7 in each probiotic group and 6 in the PBS group) using the DNeasy PowerSoil kit (Qiagen, France). The V3-V4 region of the 16S rRNA gene was amplified for 30 cycles with an annealing temperature of 65°C using *Taq* polymerase MTP (Sigma-Aldrich) and primers PCR1F_460 (CTTCCCTACACGACGCTCTCCGA TCTACGGRAGGCAGCAG) and PCR1R_460 (GGAGTTCAGACGTGTGCTCTCCGATCTTACCAGGGTATCTAATC CT). The amplicon lengths were approximately 450 bp (depending on the species). Amplicons were then sent to the Genotoul platform of INRA Toulouse (France) for sequencing. The raw 16S rRNA sequences were analyzed using the bioinformatics pipeline FROGS (Find Rapidly OTU with Galaxy Solution) (44). After quality control depletions, 622,728 total sequences (out of the initial 1,122,764 sequences), comprising 13,835 to 22,836 sequences per sample, were used for analysis. Affiliations were investigated using BLAST (Basic Local Alignment Search Tool) by reference to the SILVA 132 16S database. Data were filtered by retaining only sequences that were present in at least three samples and contributed 0.005% to the microbial community. Only sequences of sufficient quality (alignment of 400 bp and ≥ 0.95 coverage) were retained. Multiaffiliation was manually checked: each sequence was analyzed with IeBiBi (Quick Bioinformatic Phylogeny of Prokaryotes), and a single affiliation was accepted based on the results and the phylogenetic tree. The resulting OTU (operational taxonomic unit) table was used for subsequent statistical analysis using R software. The phylogenetic tree was constructed using Mafft and Fasttree on the FROGS pipeline. Samples were standardized to the same depth (13,835 sequences) before analysis.

Coincubation of the three probiotic strains with mouse bone marrow-derived dendritic cells.

(i) BMDC generation and probiotic strain preparation. Dendritic cells were generated from bone marrow collected from the femur and tibia bones of 6- to 8-week-old female BALB/cByJ mice as described previously by Lutz et al. (45). Briefly, after red cell lysis, bone marrow cells were seeded in bacteriological petri dishes containing 10 ml of Iscove's modified Dulbecco's medium (IMDM) with added streptomycin and penicillin (all from Gibco Thermo Fisher, France), 10% heat-inactivated fetal calf serum (PAN Biotech, Dutscher, France), β -mercaptoethanol (50 μM ; Sigma-Aldrich, France), and 20 ng/ml

murine recombinant GM-CSF (PeproTech, Neuilly-sur-Seine, France). Freshly prepared medium was added every 3 days, and BMDCs were used on D9 of culture. The phenotype of BMDCs was characterized according to the expression of cell surface markers, in particular CD11c, determined by FACS (fluorescence-activated cell sorting) flow cytometry analysis.

Bacterial strains were prepared as described previously (12). Briefly, they were grown in Man, Rogosa and Sharpe (MRS) medium with cysteine under anaerobic conditions ($\text{CO}_2\text{-H}_2\text{-N}_2$, 10:10:80) at 37°C up to 1 h after the start of the stationary phase. They were then washed and frozen in PBS containing 15% glycerol at -80°C until the cocubation experiments. The number of live bacteria (expressed as CFU) was estimated by culture using a Whitley automated spiral plater (WASP; AES-Chemunex, Bruz, France). Three independent growth experiments were performed for each strain.

(ii) Bacterial cell cocubation. At D9, BMDCs were seeded at 3×10^5 /well and incubated for 18 to 20 h with medium alone, TLR-2 and TLR-9 agonists (PAM2CSK4 and CpG-ODN 1825, each at 0.5 μg /well), or a single probiotic strain (multiplicity of infection [MOI], 50:1). Cells were then collected by gentle pipetting and were centrifuged for 10 min at $300 \times g$ for FACS analysis. Culture supernatants were collected and stored at -20°C for IL-10 measurement (ELISA, BD OptEIA; BD Biosciences, France).

For FACS analysis of surface marker expression, cells were resuspended in cold PBS containing 1% (vol/vol) fetal calf serum. For all staining experiments, cells were incubated with Fc receptor-blocking anti-CD32 (2.4G2). Phycoerythrin (PE)-conjugated anti-CD11c, fluorescein isothiocyanate (FITC)-conjugated MHC-II, PE-Cy7-conjugated anti-CD80, and allophycocyanin (APC)-conjugated CD86 monoclonal antibodies (MAb) and appropriate isotypic control MAb were purchased from eBiosciences, Paris, France. Cells were incubated with the appropriate MAb for 30 min on ice, then washed with 3 ml PBS-fetal bovine serum (FBS), and finally resuspended in 300 μl of 1% paraformaldehyde for flow cytometric analysis using a FACS-Accuri C6 flow cytometer (BD Biosciences). 7-Aminoactinomycin D (7-AAD) was used for staining to differentiate live and dead cells.

Statistical analysis. Results for allergic and sensitization markers, cytokines, and metabolites are expressed as medians [ranges]. Gene expression, surface markers of BMDC, and IL-10 production by BMDCs are expressed as means \pm standard errors of the means (SEM). Results were analyzed using the nonparametric Kruskal-Wallis and Mann-Whitney U tests. Differences were considered to be statistically significant when the *P* value was <0.05 . Data were analyzed using SPSS 20 software (Statistical Package for the Social Sciences; IBM, France).

For microbiota analyses, the normalized OTU table was analyzed using the Phyloseq R package to study intra- and intersample diversity (α - and β -diversity) (46). α -Diversity was studied by calculating the number of observed OTUs and the Shannon index. Statistical differences between groups were determined using Kruskal-Wallis and Mann-Whitney U tests. β -Diversity was studied using several distances (Jaccard, Bray-Curtis, and UniFrac) to analyze compositional diversity. Differences between groups were evaluated by multivariate analysis of permutation variances using distance matrices (PERMANOVA) and constrained analysis of principal coordinates (CAP). The LefSe pipeline (linear discriminant analysis [LDA] effect size) (47) was used to identify putative probiotic-related microbiota biomarkers. The LefSe algorithm uses a nonparametric factorial Kruskal-Wallis rank sum test, an unpaired Wilcoxon rank sum test, and LDA to estimate the effect size of each differentially abundant OTU; the threshold of statistical significance (α parameter) was set at 0.05 for the Kruskal-Wallis and Wilcoxon tests and at 2.0 for the logarithmic score of LDA analysis. SIMPER (similarity percentage procedure) analyses (48) were performed at the genus level. Ecologically organized heat maps were constructed using CAP ordination and Bray-Curtis dissimilarity (49).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 1 MB.

ACKNOWLEDGMENTS

N.E. has a postdoctoral contract in the framework of a collaborative project with PiLeJe Larena Health Group (2016–2018).

We thank Iharilalao Dubail and her team from the Animal Platform, Faculté de Pharmacie de Paris, for technical support in the animal experiments. We thank Vivien Paula Harry (independent medical writer), Sophie Holowacz, and Claude Blondeau (PiLeJe Larena Health Group) for careful reading of the manuscript.

A.-J.W.-D. and N.K. designed the study; N.E. was responsible for the study; N.E., A.M., J.D., C.L., C.M., M.-A.C., T.K., L.S., N.K., and A.-J.W.-D. collected data; I.N. performed the statistical analyses; N.E. and A.-J.W.-D. drafted the manuscript. N.E., A.M., N.K., and A.-J.W.-D. interpreted the data and critically revised the manuscript. All authors discussed the results, data analysis, and preparation of the manuscript.

This work was funded by a research collaborative contract between Paris Descartes University and PiLeJe Larena Health Group (France).

REFERENCES

- Mousan G, Kamat D. 2016. Cow's milk protein allergy. *Clin Pediatr (Phila)* 55:1054–1063. <https://doi.org/10.1177/0009922816664512>.
- Meyer R, Wright K, Vieira MC, Chong KW, Chatchatee P, Vlieg-Boerstra BJ, Groetch M, Dominguez-Ortega G, Heath S, Lang A, Archibald-Durham L, Rao R, De Boer R, Assa'ad A, Trewella E, Venter C. 2019. International survey on growth indices and impacting factors in children with food allergies. *J Hum Nutr Diet* 32:175–184. <https://doi.org/10.1111/jhn.12610>.
- Fox A, Bird JA, Fiocchi A, Knol J, Meyer R, Salminen S, Sitang G, Szajewska H, Papadopoulos N. 2019. The potential for pre-, pro- and synbiotics in the management of infants at risk of cow's milk allergy or with cow's milk allergy: an exploration of the rationale, available evidence and remaining questions. *World Allergy Organ J* 12:100034. <https://doi.org/10.1016/j.waojou.2019.100034>.
- Chen M, Land M. 2017. The current state of food allergy therapeutics. *Hum Vaccin Immunother* 13:2434–2442. <https://doi.org/10.1080/21645515.2017.1359363>.
- Butel MJ, Waligora-Dupriet AJ, Wydau-Dematteis S. 2018. The developing gut microbiota and its consequences for health. *J Dev Orig Health Dis* 9:590–598. <https://doi.org/10.1017/S2040174418000119>.
- Azad MB, Konya T, Guttman DS, Field CJ, Sears MR, HayGlass KT, Mandhane PJ, Turvey SE, Subbarao P, Becker AB, Scott JA, Kozyrskyj AL, CHILD Study Investigators. 2015. Infant gut microbiota and food sensitization: associations in the first year of life. *Clin Exp Allergy* 45:632–643. <https://doi.org/10.1111/cea.12487>.
- Thompson-Chagoyan OC, Fallani M, Maldonado J, Vieites JM, Khanna S, Edwards C, Dore J, Gil A. 2011. Faecal microbiota and short-chain fatty acid levels in faeces from infants with cow's milk protein allergy. *Int Arch Allergy Immunol* 156:325–332. <https://doi.org/10.1159/000323893>.
- Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, Calignano A, Khan AA, Gilbert JA, Nagler CR. 2016. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. *ISME J* 10:742–750. <https://doi.org/10.1038/ismej.2015.151>.
- Mauras A, Wopereis H, Yeop I, Esber N, Delannoy J, Labellie C, Reygnier J, Kapel N, Slump R, Eijndthoven T, Rutten L, Knol J, Garssen J, Harthoorn LF, Butel M-J, Bajaj-Elliott M, Hartog A, Waligora-Dupriet A-J. 2019. Gut microbiota from infant with cow's milk allergy promotes clinical and immune features of atopy in a murine model. *Allergy* 74:1790–1793. <https://doi.org/10.1111/all.13787>.
- Feehley T, Plunkett CH, Bao R, Choi Hong SM, Cullen E, Belda-Ferre P, Campbell E, Aitoro R, Nocerino R, Paparo L, Andrade J, Antonopoulos DA, Berni Canani R, Nagler CR. 2019. Healthy infants harbor intestinal bacteria that protect against food allergy. *Nat Med* 25:448–453. <https://doi.org/10.1038/s41591-018-0324-z>.
- Dos Santos SC, Konstantyner T, Cocco RR. 2020. Effects of probiotics in the treatment of food hypersensitivity in children: a systematic review. *Allergol Immunopathol (Madr)* 48:95–104. <https://doi.org/10.1016/j.aller.2019.04.009>.
- Neau E, Delannoy J, Marion C, Cottart CH, Labellie C, Holowacz S, Butel MJ, Kapel N, Waligora-Dupriet AJ. 2016. Three novel candidate probiotic strains with prophylactic properties in a murine model of cow's milk allergy. *Appl Environ Microbiol* 82:1722–1733. <https://doi.org/10.1128/AEM.03440-15>.
- Kostadinova AI, Middelburg J, Ciulla M, Garssen J, Hennink WE, Knippels LMJ, van Nostrum CF, Willemsen LEM. 2018. PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow's milk allergy prevention. *Eur J Pharmacol* 818: 211–220. <https://doi.org/10.1016/j.ejphar.2017.10.051>.
- Macho Fernandez E, Fernandez EM, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. 2011. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. *Gut* 60: 1050–1059. <https://doi.org/10.1136/gut.2010.232918>.
- Aalberse RC, Platts-Mills TA, Rispens T. 2016. The developmental history of IgE and IgG4 antibodies in relation to atopy, eosinophilic esophagitis, and the modified TH2 response. *Curr Allergy Asthma Rep* 16:45. <https://doi.org/10.1007/s11882-016-0621-x>.
- Wu LC, Zarrin AA. 2014. The production and regulation of IgE by the immune system. *Nat Rev Immunol* 14:247–259. <https://doi.org/10.1038/nri3632>.
- van Esch BC, Abbring S, Diks MA, Dingjan GM, Harthoorn LF, Vos AP, Garssen J. 2016. Post-sensitization administration of non-digestible oligosaccharides and Bifidobacterium breve M-16V reduces allergic symptoms in mice. *Immun Inflamm Dis* 4:155–165. <https://doi.org/10.1002/iid3.101>.
- Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT. 2012. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. *Mucosal Immunol* 5:267–276. <https://doi.org/10.1038/mi.2012.5>.
- Tordesillas L, Berin MC. 2018. Mechanisms of oral tolerance. *Clin Rev Allergy Immunol* 55:107–117. <https://doi.org/10.1007/s12016-018-8680-5>.
- McKenzie C, Tan J, Macia L, Mackay CR. 2017. The nutrition-gut microbiome-physiology axis and allergic diseases. *Immunol Rev* 278: 277–295. <https://doi.org/10.1111/imr.12556>.
- Martin-Gallausiaux C, Marinelli L, Blottiere HM, Larraufie P, Lapaque N. 2020. SCFA: mechanisms and functional importance in the gut. *Proc Nutr Soc* <https://doi.org/10.1017/S0029665120006916>.
- Goker M, Gronow S, Zeytun A, Nolan M, Lucas S, Lapidus A, Hammon N, Deshpande S, Cheng JF, Pitluck S, Liolios K, Pagani I, Ivanova N, Mavromatis K, Ovchinnikova G, Pati A, Tapia R, Han C, Goodwin L, Chen A, Palaniappan K, Land M, Hauser L, Jeffries CD, Brambilla EM, Rohde M, Detter JC, Woyke T, Bristow J, Markowitz V, Hugenholtz P, Eisen JA, Kyrpidis NC, Klenk HP. 2011. Complete genome sequence of *Odoribacter splanchnicus* type strain (1651/6). *Stand Genomic Sci* 4:200–209. <https://doi.org/10.4056/sigs.1714269>.
- Abdel-Gadir A, Stephen-Victor E, Gerber GK, Noval Rivas M, Wang S, Harb H, Wang L, Li N, Crestani E, Spielman S, Secor W, Biehl H, DiBenedetto N, Dong X, Umetsu DT, Bry L, Rachid R, Chatila TA. 2019. Microbiota therapy acts via a regulatory T cell MyD88/ROR γ t pathway to suppress food allergy. *Nat Med* 25:1164–1174. <https://doi.org/10.1038/s41591-019-0461-z>.
- Dehhaghi M, Kazemi Shariat Panahi H, Guillemin GJ. 2019. Microorganisms, tryptophan metabolism, and kynurenine pathway: a complex interconnected loop influencing human health status. *Int J Tryptophan Res* 12:1178646919852996. <https://doi.org/10.1177/1178646919852996>.
- Georgin-Lavialle S, Launay JM, Cote F, Soucie E, Soria A, Damaj G, Moura DS, Canioni D, Hanssens K, Chandresris MO, Barete S, Dubreuil P, Lortholary O, Hermine O, Sokol H. 2016. Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. *Allergy* 71:416–420. <https://doi.org/10.1111/all.12802>.
- Perezabad L, Reche M, Valbuena T, Lopez-Fandino R, Molina E, Lopez-Exposito I. 2017. Oral food desensitization in children with IgE-mediated cow's milk allergy: immunological changes underlying desensitization. *Allergy Asthma Immunol Res* 9:35–42. <https://doi.org/10.4168/air.2017.9.1.35>.
- Simonyte Sjodin K, Hammarstrom ML, Ryden P, Sjodin A, Hernell O, Engstrand L, West CE. 2019. Temporal and long-term gut microbiota variation in allergic disease: a prospective study from infancy to school age. *Allergy* 74:176–185. <https://doi.org/10.1111/all.13485>.
- Kleinjans L, Veening-Griffioen DH, Wehkamp T, van Bergenhenegouwen J, Knol J, Garssen J, Knippels LMJ, Belzer C, Jeurink PV. 2019. Mice co-administrated with partially hydrolysed whey proteins and prebiotic fibre mixtures show allergen-specific tolerance and a modulated gut microbiota. *Benef Microbes* 10:165–178. <https://doi.org/10.3920/BM2018.0001>.
- Shenker BJ, Vitale L, Slots J. 1991. Immunosuppressive effects of *Prevotella intermedia* on in vitro human lymphocyte activation. *Infect Immun* 59: 4583–4589. <https://doi.org/10.1128/AI.59.12.4583-4589.1991>.
- Schulke S. 2018. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. *Front Immunol* 9:455. <https://doi.org/10.3389/fimmu.2018.00455>.
- Escobar A, Aguirre A, Guzman MA, Gonzalez R, Catalan D, Acuna-Castillo C, Larrondo M, Lopez M, Pesce B, Rolland J, O'Hehir R, Aguilon JC. 2014. Tolerogenic dendritic cells derived from donors with natural rubber latex allergy modulate allergen-specific T-cell responses and IgE production. *PLoS One* 9:e85930. <https://doi.org/10.1371/journal.pone.0085930>.
- Hasegawa H, Matsumoto T. 2018. Mechanisms of tolerance induction by dendritic cells in vivo. *Front Immunol* 9:350. <https://doi.org/10.3389/fimmu.2018.00350>.
- Fu G, Zhao K, Chen H, Wang Y, Nie L, Wei H, Wan C. 2019. Effect of 3

- lactobacilli on immunoregulation and intestinal microbiota in a beta-lactoglobulin-induced allergic mouse model. *J Dairy Sci* 102:1943–1958. <https://doi.org/10.3168/jds.2018-15683>.
34. Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, Yuan L, Wang Y, Sun J, Li L, Xiang C. 2014. Altered fecal microbiota composition associated with food allergy in infants. *Appl Environ Microbiol* 80:2546–2554. <https://doi.org/10.1128/AEM.00003-14>.
 35. Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, Hamelmann E. 2013. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. *J Allergy Clin Immunol* 132:601–607 e8. <https://doi.org/10.1016/j.jaci.2013.05.043>.
 36. Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, Beyer K, Bindslev-Jensen C, Burks W, Ebisawa M, Eigenmann P, Knol E, Nadeau KC, Poulsen LK, van Ree R, Santos AF, Du Toit G, Dhimi S, Nurmatov U, Boloh Y, Makela M, O'Mahony L, Papadopoulos N, Sackesen C, Agache I, Angier E, Halken S, Jutel M, Lau S, Pfaar O, Ryan D, Sturm G, Varga EM, van Wijk RG, Sheikh A, Muraro A, EAACI Allergen Immunotherapy Guidelines Group. 2018. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. *Allergy* 73:799–815. <https://doi.org/10.1111/all.13319>.
 37. Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, Licciardi P, Burks W, Donath S. 2015. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. *J Allergy Clin Immunol* 135:737–744 e8. <https://doi.org/10.1016/j.jaci.2014.11.034>.
 38. Li XM, Schofield BH, Huang CK, Kleiner GI, Sampson HA. 1999. A murine model of IgE-mediated cow's milk hypersensitivity. *J Allergy Clin Immunol* 103:206–214. [https://doi.org/10.1016/S0091-6749\(99\)70492-6](https://doi.org/10.1016/S0091-6749(99)70492-6).
 39. Rodriguez B, Prioult G, Hacini-Rachinel F, Moine D, Bruttin A, Ngom-Bru C, Labellie C, Nicolis I, Berger B, Mercenier A, Butel MJ, Waligora-Dupriet AJ. 2011. Infant gut microbiota is protective against cow's milk allergy in mice despite immature ileal T-cell response. *FEMS Microbiol Ecol* 79: 192–202. <https://doi.org/10.1111/j.1574-6941.2011.01207.x>.
 40. Menard O, Butel MJ, Gaboriau-Routhiau V, Waligora-Dupriet AJ. 2008. Gnotobiotic mouse immune response induced by *Bifidobacterium* sp. strains isolated from infants. *Appl Environ Microbiol* 74:660–666. <https://doi.org/10.1128/AEM.01261-07>.
 41. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods* 25:402–408. <https://doi.org/10.1006/meth.2001.1262>.
 42. Lan A, Bruneau A, Bensaada M, Philippe C, Bellaud P, Rabot S, Jan G. 2008. Increased induction of apoptosis by *Propionibacterium freudenreichii* TL133 in colonic mucosal crypts of human microbiota-associated rats treated with 1,2-dimethylhydrazine. *Br J Nutr* 100:1251–1259. <https://doi.org/10.1017/S0007114508978284>.
 43. Evans AM, Bridgewater BR, Liu Q, Mitchell MW, Robinson RJ, Dai H, Stewart SJ, DeHaven CD, Miller LAD. 2014. High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput profiling metabolomics. *Metabolomics* 4. <https://doi.org/10.4172/2153-0769.1000132>.
 44. Escudie F, Auer L, Bernard M, Mariadassou M, Cauquil L, Vidal K, Maman S, Hernandez-Raquet G, Combes S, Pascal G. 2018. FROGS: Find, Rapidly, OTUs with Galaxy Solution. *Bioinformatics* 34:1287–1294. <https://doi.org/10.1093/bioinformatics/btx791>.
 45. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods* 223:77–92. [https://doi.org/10.1016/S0022-1759\(98\)00204-x](https://doi.org/10.1016/S0022-1759(98)00204-x).
 46. McMurdie PJ, Holmes S. 2013. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS One* 8:e61217. <https://doi.org/10.1371/journal.pone.0061217>.
 47. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. 2011. Metagenomic biomarker discovery and explanation. *Genome Biol* 12:R60. <https://doi.org/10.1186/gb-2011-12-6-r60>.
 48. Clarke KR. 1993. Non-parametric multivariate analyses of changes in community structure. *Austral Ecol* 18:117–143. <https://doi.org/10.1111/j.1442-9993.1993.tb00438.x>.
 49. Rajaram S, Oono Y. 2010. NeatMap—non-clustering heat map alternatives in R. *BMC Bioinformatics* 11:45. <https://doi.org/10.1186/1471-2105-11-45>.